Article

Strides Said to Consider Sale of Injectable-Drugs Unit

Strides Arcolab Ltd. (STR)

, a supplier of cancer-fighting drugs to Pfizer Inc., is considering selling its injectable-medicines unit, three people with knowledge of the matter said.

market value

The unit, called Agila Specialties, may be valued at more than Bangalore-based Strides’s current of about $800 million, two people said, declining to be identified as the information is private. Agila’s relative success in winning approvals for new products and the scarcity of facilities able to manufacture injectable medicines make it an attractive target for drugmakers, they said.

Read the full story: http://tinyurl.com/9c5zogt

Source: Bloomberg

Newsletter

Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.

Related Videos
Dr Caroline Vovan
Dr María Díez Campelo
1 expert in this video
1 expert in this video
Dr Hans Lee
Dr María Díez Campelo
AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo